RecruitingPhase 4NCT07212803

Effects of Energy Drinks on Cardiovascular Endpoints

Evaluation of Energy Drinks on Electrocardiographic Parameters: A Randomized, Double Blind, Controlled, Crossover, Proof-of-concept Study


Sponsor

University of the Pacific

Enrollment

3 participants

Start Date

Nov 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is a clinical trial looking at the impact of energy drinks on heart related parameters. The study will enroll 3 participants who will be exposed to 8 different interventions.


Eligibility

Min Age: 18 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how energy drinks affect the heart and blood vessels in healthy young adults. Participants will consume energy drinks and have their heart activity monitored during study visits. **You may be eligible if...** - You are a healthy adult between 18 and 40 years old - You are willing to avoid caffeine and alcohol for 72 hours before each study visit - You are willing to fast (no food) for 10 hours before study visits - You have active health insurance - You are not pregnant or breastfeeding **You may NOT be eligible if...** - You have any heart condition, diabetes, thyroid disease, kidney or liver problems, or any other significant medical condition - You take any daily medications, supplements, or herbal products - You smoke or use any nicotine or tobacco products - You are underweight - You have an allergy to taurine or nuts - You are currently enrolled in another clinical study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTEnergy Drink A + Placebo Capsule

1000 mL caffeine- and taurine-containing commercially available beverage (Formula A) consumed with placebo capsule

DRUGPlacebo Drink + Moxifloxacin Capsule

Placebo drink with 400 mg moxifloxacin capsule

DIETARY_SUPPLEMENTPlacebo Drink + Caffeine Capsule

Placebo drink with 320 mg caffeine capsule

OTHERPlacebo Drink + Placebo Capsule

Placebo drink with placebo capsule

DIETARY_SUPPLEMENTEnergy Drink B

568 mL caffeine- and taurine-containing commercially available beverage (Formula B)

DIETARY_SUPPLEMENTControl Product + Taurine

Control product with 4000 mg taurine powder

DIETARY_SUPPLEMENTControl Product + Caffeine + Taurine

Control product with 320 mg caffeine + 4000 mg taurine powder

DIETARY_SUPPLEMENTLower Dose Energy Drink A

591 mL caffeine- and taurine-containing commercially available beverage (Formula A)


Locations(1)

University of the Pacific

Stockton, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07212803


Related Trials